BSE filing, NSE: MACINTR. Summary written from the filing by ALFA Finder's alert engine.
Astal Laboratories Ltd: key numbers
- Share price
- ₹64.10
- Market cap
- ₹270.6 Cr
- Revenue (annual)
- ₹156.0 Cr
- Net profit (annual)
- ₹8.12 Cr
- P/E (TTM)
- 27.8×Sector 36.4×
- Promoter holding
- 4.59%+0.06% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Astal Laboratories Ltd
All →Astal Laboratories Other Announcement
Astal Laboratories submitted the Regulation 74(5) certificate from its Registrar for the quarter ended September 30, 2026, confirming the dematerialization activities.
Astal Laboratories Other Announcement
Astal Laboratories' material subsidiary, Sriven Pharmachem India, appointed new Internal, Cost, and Secretarial Auditors. The appointments were approved during the subsidiary's board meeting on September 28, 2026.
Astal Laboratories Management Change
Astal Laboratories Limited has appointed Ms. Ambika Kedia as Company Secretary of its material wholly-owned subsidiary, Sriven Pharmachem India Private Limited. The appointment is effective from September 28, 2026.
Astal Laboratories Annual General Meeting
Astal Laboratories held its 33rd Annual General Meeting on September 29, 2026. Members transacted business regarding financial statements and the re-appointment of a director.
Astal Laboratories Promoter Buying: ₹0.2 Cr
Promoter Aceso Research Labs LLP acquired 25,417 equity shares of Astal Laboratories Ltd via market purchase, increasing their stake from 4.53% to 4.59%.
- Value
- ₹0.20 Cr
- Promoter stake change
- +0.06%
Astal Laboratories Promoter Buying
Astal Laboratories' promoter ACESO Research Labs LLP bought equity shares on BSE under a SEBI PIT disclosure. The open-market purchase signals promoter confidence.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.